#### Amendments to the Specification:

At the end of the application, please replace the current Sequence Listing with the attached paper and computer-readable Sequence Listing.

Please insert the following heading after the paragraph ending on line 2 of page 1:

#### **BACKGROUND**

Please insert the following heading after the paragraph ending on line 12 of page 4:

### **SUMMARY**

Please replace the paragraph beginning on page 74, line 22, with the following rewritten paragraph:

The vectors of the invention can also comprise sequences required for targeting the peptides to specific cellular compartments. An example of targeting may be the targeting to the endoplasmic reticulum obtained using targeting sequences of the type such as the leader sequence derived from the adenoviral E3 protein (Ciernik I.F., et al., The Journal of Immunology, 199, 162, 3915–3925Ciernik et al., The Journal of Immunology; 1996; 156; 2369-2375).

Please insert the following heading after the paragraph ending on line 15 of page 81:

## BRIEF DESCRIPTION OF THE DRAWINGS

Please replace the paragraph beginning on page 81, line 36, with the following rewritten paragraph:

- Figure 3 represents the alignment of the consensus sequences of genotypes 1b (SEQ ID NO: 2) (Figure 3A) and 3 (SEQ ID NO: 152) (Figure 3B), with the A9L (SEQ ID NO: 177 in Figure 3A; SEQ ID NO: 435 in Figure 3B), W9L (SEQ ID NO: 236 in Figure 3A; SEQ ID NO: 267 in Figure 3B), R9V (SEQ ID NO: 284 in Figure 3A; SEQ ID NO: 436 in Figure 3B) and G9L (SEQ ID NO: 359 in both Figures 3A and 3B) epitopes.

Please insert the following heading at the top on page 82:

# **DETAILED DESCRIPTION OF EMBODIMENTS**